Alumis Inc

ALMS

Market cap $3.65B

SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026, at 10:40 a.m. ET.

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences:

BML Capital Management sold 1,210,415 shares of Alumis in the fourth quarter. The shares were worth about $4.83 million as of the last-disclosed values.

In the past week, a beneficial owner has continued to build a stake in insurance giant W.R.

Acquisition of 588,235 shares at $17.00 per share, representing a total transaction value of ~$10.0 million as of Jan. 9, 2026. This purchase represented 46.49% of Srinivas Akkaraju's previously reported indirect holdings.

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the closing of its upsized underwritten public offering of 20,297,500 shares of its common stock, including the full exercise of the underwriters' option to purchase an additional 2,647,500 shares, at a price to the public of $17.00 per share.

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the pricing of an upsized underwritten public offering of 17,650,000 shares of its common stock at a price to the public of $17.00 per share.

Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong skin clearance.

Alumis Inc. surged 95% after reporting strong Phase 3 results for lead candidate envudeucitinib in moderate-to-severe plaque psoriasis. Envudeucitinib demonstrated high efficacy for an oral agent, with two-thirds achieving PASI 90 and over 40% reaching complete clearance by Week 24. ALMS announced a $175 million public offering to fund regulatory and clinical advancement, with a 2026 NDA submission targeted.

Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh capital.